Skip to main content
. 2015 Sep 30;10(2):195–212. doi: 10.1016/j.molonc.2015.09.008

Figure 5.

Figure 5

The effect of SB‐258719 on patient‐derived primary HCC cultures. (A) SB‐258719 attenuated the growth of patient‐derived primary HCC cultures in the presence of 5‐HT and cell viability was detected by MTT. (B) SB‐258719 down‐regulated the expression of β‐catenin in patient‐derived primary HCC cultures compared to 5‐HT treatment only.